Stock Gumshoe
Become a member

Elliot

Author Archives

June 10, 2014

AAPL

I’m wondering if anyone has any thoughts on some profit taking in AAPL at this time. I’m thinking about taking 33% off the table, as I have reached my long term capital gains period with this portion of my investment. The stock is obviously red hot lately, though, and I’ve always heard to never sell […]

Recent Author Comments

On The Twelve Biotechs of Christmas 2018: Balthasar
Posted on January 12, 2018
$CWBR Thanks for the Christmas gift, Doc. Weird (and possibly stupid) question that just kind of came to mind. I doubt it’s been discussed before. Do treatments like MOTS-C alter one’s genetic makeup? Is there any chance treatments like these and gene [...]
On Microblog: Scandium, Cobalt, and Water Purification: CleanTeQ Holdings
Posted on November 17, 2017
Electric semi trucks will further drive nickel and cobalt demand higher https://www.bloomberg.com/amp/news/articles/2017-11-17/tesla-truck-supercharges-hopes-for-boom-in-battery-metals-demand long $CTEQF[...]
On Tear Sheet: CohBar Inc. ($CWBR)
Posted on October 9, 2017
Keep dissing the gummie community and the money will dry up. Talking down to people and calling us pathetic just because two people suggest that maybe we should go a little easy on the kool-aid is a sure way to kill a great thread. I know I'm getting fed[...]
On Oncotutorial
Posted on July 8, 2017
MY TOP 10 BIOTECH HOLDINGS NO ORDER: ESPR AKAO AUPH AKBA RDUS BLUE CLVS PTLA SGEN AAVXF[...]
On Long Idea of the Year
Posted on June 18, 2017
$FGRRF I've been noticing Fingerprint cards AB coming up a lot, and I have not followed too closely. Maybe this has already come up, but last I heard they were struggling https://www.bloomberg.com/news/articles/2017-03-21/fingerprint-cards-withdraws-divide[...]
On Long Idea of the Year
Posted on May 16, 2017
$AKAO - Anyone know what the hell this Form D is from Akaogen? Never seen one of these before, looks odd. Long $AKAO[...]
On Long Idea of the Year
Posted on May 15, 2017
$AKBA on fire lately. Lots of good things going for this company. CAMBRIDGE, Mass. & ZURICH--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA) and Vifor Pharma Group. today announced they have entered into an exclusive license agreement to s[...]
On Long Idea of the Year
Posted on May 13, 2017
Stick to the important things- biotech discussions... that's what I'm talkin about, LostOkie![...]
On Long Idea of the Year
Posted on May 12, 2017
Gummies, I beg you, please stop feeling the need to individually respond scoldingly to every negative post that comes up here. You're wasting so much time for many people reading notifications. These people aren't deserving of a response. If you feel the n[...]
On Long Idea of the Year
Posted on April 28, 2017
Bought into Radius Health ($RDUS) just the other day. I'm having some amazing timing lately. FDA Approves Radius Health's TYMLOS(TM) (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fract[...]
On The Conversation: ScyNexis ($SCYX) CFO Eric Francois
Posted on April 25, 2017
$AKBA Akebia and Otsuka Expand Relationship with Collaboration to Develop and Commercialize Vadadustat in Europe, China and Other Territories Maximizes Efficiency of Global Development and Commercialization Committed Capital and Potential Milestone Pay[...]
On The Conversation: ScyNexis ($SCYX) CFO Eric Francois
Posted on April 22, 2017
Subscribe link?[...]
On The Rest of the 12 Biotechs of Christmas
Posted on March 13, 2017
long $AUPH :)[...]
On The Rest of the 12 Biotechs of Christmas
Posted on March 13, 2017
$AUPH public offering. First real test http://ir.auriniapharma.com/press-releases/detail/77[...]
On The Rest of the 12 Biotechs of Christmas
Posted on March 13, 2017
Doing some trading today, huh, doc? :) me too ... just entered $AKBA! Long overdue that I own this one, ready for takeoff now :)[...]
On The Rest of the 12 Biotechs of Christmas
Posted on March 11, 2017
SORRY if it's already already been discued but someone explain to me the situation NEw mountain advisors is in with $BLph? ALso, why can't I post normally on this thread? Caps is all jacked up[...]
On Noblecon13 Live Blog
Posted on February 3, 2017
New buy for me today - Kindred Biosciences $KIN. Not sure if this one has come up here before, but it's another animal health care biotech that looks quite cheap at 2x cash with no debt. Lots in the pipeline. Has seen massive insider buying lately and ha[...]
On The Twelve Biotechs of Christmas: One
Posted on February 3, 2017
nice pop today in $ESPR on 10x average volume and no apparent news. Broke through key short term resistance. Filled the gap down from June 2016. Long $ESPR[...]
On The Twelve Biotechs of Christmas: One
Posted on January 30, 2017
Bit the bullet and quadrupled my position in $ESPR today. Granted, I sold off most for a nice profit last year, and then the share price hasn't been crushed so my position became quite small. Very much over sold here imo and institutional investors seem to[...]
On Such A Pleasant Stay
Posted on December 14, 2016
phew ... I mean, good for you if it had been your biggest holding, but you would have to be nuts to be positioned in that way[...]

This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

Connect with Travis

website designed by Gravity Switch